ArticleCureus2025
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use and Inflammatory Markers Among U.S. Adults: A National Health and Nutrition Examination Survey (NHANES)-Based Analysis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic inflammation plays a critical role in the development of obesity-related complications, type 2 diabetes mellitus (T2DM), and cardiovascular disease. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for glycemic control and weight management, with emerging evidence suggesting potential anti-inflammatory effects.
objectiveTo examine the association between GLP-1RA use and systemic inflammation, measured by high-sensitivity C-reactive protein (hs-CRP), in a nationally representative sample of U.S. adults.
methodsWe conducted a cross-sectional analysis using National Health and Nutrition Examination Survey (NHANES) 2005-2010 data. Survey-weighted linear regression models were used to assess the relationship between GLP-1 use and log-transformed CRP, adjusting for demographic, socioeconomic, and clinical factors.
resultsGLP-1 users had significantly higher CRP levels in unadjusted models (β=1.081, p<0.01). However, after adjusting for age, gender, race/ethnicity, income, body mass index (BMI), diabetes, glycated hemoglobin (HbA1c), and smoking, the association was no longer statistically significant (β=0.323, p=0.38). Clinical factors accounted for most of the variance.
conclusionIn this cross-sectional, population-based analysis, GLP-1RA use was not independently associated with lower systemic inflammation after accounting for demographic and clinical confounders. The higher hs-CRP observed among GLP-1 users in unadjusted models is most consistent with confounding by indication and greater cardiometabolic disease burden among treated individuals rather than a direct pro-inflammatory effect of the medications. Longitudinal studies with larger contemporary samples (including newer GLP-1 agents) and repeated inflammatory measures are needed to clarify whether GLP-1 therapies exert direct anti-inflammatory effects beyond their metabolic benefits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.